Institutional members access full text with Ovid®

A Reminder About Teratogenic Risk With Valproate

Aschenbrenner, Diane S. MS, APRN-BC

AJN, American Journal of Nursing: May 2010 - Volume 110 - Issue 5 - pp 24-25
doi: 10.1097/01.NAJ.0000372066.93639.af
Drug Watch

* The antiepileptic valproate sodium and its derivatives are increasingly being used to treat conditions other than epilepsy.

* Providers are reminded by the FDA about the risks of major birth defects in babies born to women who take these medications.

* Risks include neural tube defects, craniofacial defects, and cardiovascular malformations.

Diane S. Aschenbrenner is the course coordinator for undergraduate pharmacology at Johns Hopkins University School of Nursing in Baltimore, MD. She also coordinates Drug Watch: dianea@son.jhmi.edu.

© 2010 Lippincott Williams & Wilkins, Inc.